In today’s world, it is unconscionable to think a female patient would be denied testing or have a hemophilia diagnosis ...

A Summerville man became the first person in South Carolina to undergo potentially life-changing gene therapy. The treatment took place Thursday morning at Prisma Health's Hemophilia Treatment Center ...

The decision to discontinue SerpinPC follows the approval of Hympavzi, an antibody-based treatment designed to increase ...

Oct. 14, 2024 – The FDA has approved a new preventive treatment for people with certain types of hemophilia that can reduce bleeding episodes, sometimes down to just a few per year.

Friday Headlines: 38 y/o Brent Maloy is the first person in SC to undergo gene therapy treatment after living with Hemophilia ...

Routine blood draws during a doctor’s visit can reveal disorders or diseases and as the number of patient caseloads inches ...

Joint damage and chronic pain persist in hemophilia, especially in low-resource settings, necessitating innovative therapies and early diagnostic tools. Extended half-life products and emerging ...

As many as 30% of people living with severe hemophilia A develop inhibitors such as TFPI, which can be produced by the body’s immune response to clotting factors in replacement therapy, often limiting ...

The approval is based on an open-label, multicenter study of 116 adult and pediatric male patients with either severe hemophilia A or severe hemophilia B, both without inhibitors. For the first ...

FIX in hemophilia B), impacting more than 800,000 people globally. Results from the Phase 3 BASIS trial (NCT03938792) supported the FDA approval of Hympavzi. In the study, Hympavzi reduced the ...